share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  06/25 17:21
Moomoo AI 已提取核心信息
On June 24, 2024, eFFECTOR Therapeutics, Inc. received a notification from Nasdaq's Listing Qualifications Staff indicating that the company is considered a 'public shell' following its announcement to terminate employees and wind down operations. This determination was made because eFFECTOR Therapeutics no longer meets Nasdaq's listing requirements, including those related to board independence and committee compositions. Additionally, the company has failed to maintain the minimum market value of listed securities of $35 million, a non-compliance issue previously disclosed on May 17, 2024. Consequently, Nasdaq plans to suspend trading of eFFECTOR Therapeutics' common stock on July 3, 2024, and will proceed with delisting the company's securities. eFFECTOR Therapeutics has decided not to appeal this decision and intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act of 1934.
On June 24, 2024, eFFECTOR Therapeutics, Inc. received a notification from Nasdaq's Listing Qualifications Staff indicating that the company is considered a 'public shell' following its announcement to terminate employees and wind down operations. This determination was made because eFFECTOR Therapeutics no longer meets Nasdaq's listing requirements, including those related to board independence and committee compositions. Additionally, the company has failed to maintain the minimum market value of listed securities of $35 million, a non-compliance issue previously disclosed on May 17, 2024. Consequently, Nasdaq plans to suspend trading of eFFECTOR Therapeutics' common stock on July 3, 2024, and will proceed with delisting the company's securities. eFFECTOR Therapeutics has decided not to appeal this decision and intends to file a Form 15 to suspend its reporting obligations under the Securities Exchange Act of 1934.
2024年6月24日,eFFECTOR Therapeutics收到纳斯达克上市资格工作人员的通知,表明公司被认为是一个'公共外壳',因为它宣布要解雇员工并停止运营。这个决定是由于eFFECTOR Therapeutics不再符合纳斯达克的上市要求,包括与董事会独立性和委员会组成相关的要求。此外,该公司未能保持上市证券的最低市值为3500万美元,这是一个非合规问题,于2024年5月17日已经披露。因此,纳斯达克计划在2024年7月3日暂停eFFECTOR Therapeutics普通股的交易,并将继续摘牌该公司的证券。eFFECTOR Therapeutics已决定不上诉此决定,并打算提交15表格以暂停其根据1934年证券交易法的报告义务。
2024年6月24日,eFFECTOR Therapeutics收到纳斯达克上市资格工作人员的通知,表明公司被认为是一个'公共外壳',因为它宣布要解雇员工并停止运营。这个决定是由于eFFECTOR Therapeutics不再符合纳斯达克的上市要求,包括与董事会独立性和委员会组成相关的要求。此外,该公司未能保持上市证券的最低市值为3500万美元,这是一个非合规问题,于2024年5月17日已经披露。因此,纳斯达克计划在2024年7月3日暂停eFFECTOR Therapeutics普通股的交易,并将继续摘牌该公司的证券。eFFECTOR Therapeutics已决定不上诉此决定,并打算提交15表格以暂停其根据1934年证券交易法的报告义务。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息